Literature DB >> 8560577

Hodgkin's disease after transplantation.

J L Garnier1, Y Lebranchu, J Dantal, J Bedrossian, R Cahen, D Assouline, A Jaccard, F Fetissoff, A Moreau, X Martin, G Delsol, F Berger, J L Touraine.   

Abstract

Hodgkin's disease (HD) has seldom been reported after transplantation. Epstein-Barr virus (EBV) is present in about 50% of Reed-Sternberg cells in HD developing in immunocompetent individuals, but is more frequently found in HD of acquired immune deficiency syndrome patients. We report 7 cases of HD that occurred in transplant recipients. Clinical and pathological data and studies of EBV reveal specific features of HD after transplantation. Six patients received kidney transplants and 1 patient received combined kidney and pancreas transplantation. Immunosuppressive therapy consisted of cyclosporine, steroids, azathioprine, and antilymphocyte globulins. One patient received, in addition, anti-CD3 mAb therapy and an EBV+ B cell lymphoma developed. Retrospective EBV serological data from patients were collected. Tumors were classified according to pathology. EBV studies were conducted by immunohistochemical methods with monoclonal antibodies to EBV-latent membrane protein (LMP) or EBV-nuclear antigen 2 (EBNA2), and by in situ hybridization for latent nuclear EBV-early RNAs (EBERs). The mean lapse of time between transplantation and HD was 49 months. Six patients presented with enlarged lymph nodes and 1 patient presented with liver involvement. HD was classified as IA in 2 patients, IIA in 3 patients, IIIB in 1 patient, and IVB in 1 patient. Four patients had primary EBV infection after graft, before HD, and the others reactivated latent EBV infection. Histological subtypes were mixed cellularity in 6 cases and lymphocytic depletion in 1 case. Latent EBV infection was detected with EBERs in all tumors. Reed-Sternberg cells expressed LMP, and were negative for EBNA2 expression. Six patients were treated: 2 patients at stage I received radiotherapy, and relapsed within 1 year with a more advanced stage of HD; chemotherapy was indicated as primary therapy in 5 patients, and as salvage therapy in 2 patients; it was associated with radiotherapy in 4 patients. Immunosuppressive therapy was reduced in all patients. Four patients were alive and in complete remission 18, 25, 31, and 67 months after chemotherapy, with a functioning graft in 3 patients. Two patients died of infection. Mixed cellularity is the most frequent histological subtype observed in HD occurring in transplant patients. EBV is present in all Reed-Sternberg cells. Posttransplant HD shows similarities with human immunodeficiency virus-associated HD. These facts argue for a role of EBV infection and immunosuppression in the progression of HD after transplantation.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8560577     DOI: 10.1097/00007890-199601150-00015

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  8 in total

1.  Hodgkin lymphoma among US solid organ transplant recipients.

Authors:  Scott C Quinlan; Ola Landgren; Lindsay M Morton; Eric A Engels
Journal:  Transplantation       Date:  2010-11-15       Impact factor: 4.939

2.  Epstein-Barr virus gene expression in post-transplant lymphoproliferative disorders.

Authors:  M Rowe; G Niedobitek; L S Young
Journal:  Springer Semin Immunopathol       Date:  1998

3.  Epstein-Barr virus-associated Hodgkin's disease following renal transplantation.

Authors:  Jung-Hye Choi; Myung-Ju Ahn; Young-Ha Oh; Sang-Woong Han; Ho-Jung Kim; Young-Yeul Lee; In-Soon Kim
Journal:  Korean J Intern Med       Date:  2006-03       Impact factor: 2.884

4.  Hodgkin lymphoma post-transplant lymphoproliferative disorder: A comparative analysis of clinical characteristics, prognosis, and survival.

Authors:  Aaron S Rosenberg; Andreas K Klein; Robin Ruthazer; Andrew M Evens
Journal:  Am J Hematol       Date:  2016-04-26       Impact factor: 10.047

Review 5.  Epstein-Barr virus infection and human malignancies.

Authors:  G Niedobitek; N Meru; H J Delecluse
Journal:  Int J Exp Pathol       Date:  2001-06       Impact factor: 1.925

6.  Cyclosporine exacerbates ketamine toxicity in zebrafish: Mechanistic studies on drug-drug interaction.

Authors:  Bonnie L Robinson; Melanie Dumas; Syed F Ali; Merle G Paule; Qiang Gu; Jyotshna Kanungo
Journal:  J Appl Toxicol       Date:  2017-06-01       Impact factor: 3.446

7.  Rectal Hodgkin lymphoma in a patient with ulcerative colitis: a case study.

Authors:  Simon Ladefoged Rasmussen; Christian Thomsen
Journal:  Diagn Pathol       Date:  2015-04-16       Impact factor: 2.644

8.  Blood Epstein-Barr virus DNA does not predict outcome in advanced HIV-associated Hodgkin lymphoma.

Authors:  Ikram Ul-Haq; Alessia Dalla Pria; Elisa Suardi; David J Pinato; Fieke Froeling; John Forni; Paul Randell; Mark Bower
Journal:  Med Oncol       Date:  2018-03-13       Impact factor: 3.064

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.